NCT05445674 is a Phase 2 clinical trial of Plasma Exchange Procedure in Post-COVID19 Condition, sponsored by Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia.

What drugs are being tested in NCT05445674?

Interventions in NCT05445674: Plasma Exchange Procedure, Sham Plasma Exchange Procedure.

What condition does NCT05445674 study?

NCT05445674 studies Post-COVID19 Condition.

Is NCT05445674 still recruiting?

NCT05445674 is currently completed. Last updated 7 June 2023.

Last reviewed 2023-06-07 · How we verify

NCT05445674

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Plasma Exchange Therapy for Post- COVID-19 Condition: A Pilot, Randomized Double-Blind Study

Completed Phase 2 Last updated 7 June 2023

What this trial tests

Phase 2 trial testing Plasma Exchange Procedure in Post-COVID19 Condition in 50 participants. Completed in 6 June 2023.

Timeline

22 September 2022

Primary endpoint
6 June 2023

6 June 2023

Quick facts

Lead sponsor	Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	50
Start date	22 September 2022
Primary completion	6 June 2023
Estimated completion	6 June 2023
Sites	1 location across Spain

Drugs / interventions tested

Plasma Exchange Procedure
Sham Plasma Exchange Procedure

Conditions studied

Post-COVID19 Condition — all drugs for Post-COVID19 Condition →

Sponsor

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia — full company profile →

Who can join

Adults 18 to 100, any sex, with Post-COVID19 Condition. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PAX is a prospective, randomized (1:1), double-blind, placebo-controlled study, that have as a objective to evaluate the safety and tolerability of plasma exchange (PE) in patients with Post Acute Covid-19 Syndrome (PCC) comparing to sham plasma exchange. The participants will be randomized in two arms: (1) 6 sessions of PE (Plasma Exchange) with human serum albumin 5% or (2) 6 sessions with placebo (infusion of of sterile saline solution 0.9%) on days 1, 3, 8, 10, 15 and 17.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Fighting Post-COVID and ME/CFS - development of curative therapies.
Scheibenbogen C, Bellmann-Strobl JT, Heindrich C, Wittke K, et al · · 2023 · cited 32× · PMID 37396922 · DOI 10.3389/fmed.2023.1194754
Biological mechanisms underpinning the development of long COVID.
Perumal R, Shunmugam L, Naidoo K, Wilkins D, et al · · 2023 · cited 26× · PMID 37265584 · DOI 10.1016/j.isci.2023.106935
Plasmapheresis to remove amyloid fibrin(ogen) particles for treating the post-COVID-19 condition.
Fox T, Hunt BJ, Ariens RA, Towers GJ, et al · · 2023 · cited 14× · PMID 37491597 · DOI 10.1002/14651858.cd015775
Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial.
España-Cueto S, Loste C, Lladós G, López C, et al · · 2025 · cited 6× · PMID 39994269 · DOI 10.1038/s41467-025-57198-7

Verify or expand the search:

Other Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia trials

Trials by the same sponsor.

NCT07264686 — Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG - Second Trial · Phase 2 · active not recruiting
NCT07267390 — Investigating MPXV Viral Clearance in Mpox Cases and Secondary Attack Rate in Contacts · recruiting
NCT07197164 — Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients · Phase 2 · recruiting
NCT06766825 — Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC) · Phase 2 · recruiting
NCT06690814 — Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05445674 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Last refreshed: 7 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05445674.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing